Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s [...]
Genentech, a member of the Roche Group, was founded more than 35 years ago and has been focused on a variety of research fields, including [...]
Results from a Phase 2 clinical trial showed that five-year clinical outcomes of patients with highly active relapsing-remitting multiple [...]
Results from the STRIVE study support the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. The study, [...]
A study of relapsing-remitting multiple sclerosis (RRMS) patients who had one or more relapses on earlier treatment, showed [...]
Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release [...]
Stem cell treatment of MS, which came under the spotlight at last week’s 16th Annual Meeting of the Consortium of Multiple Sclerosis [...]
A study, recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in National Harbor, Md., showed MS [...]
Mayis Al Dughmi, of the Physical Therapy and Rehabilitation Science at the University of Kansas Medical Center, recently presented her [...]
CMSC 2016 Annual Meeting – multiple sclerosis research highlights what improves with clinical care
Melissa A. Colbeck, an investigator at the Occupational Therapy, Health Sciences Centre in Winnipeg, Canada, studied how different [...]
